PMID- 35802255
OWN - NLM
STAT- MEDLINE
DCOM- 20220729
LR  - 20220803
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 82
IP  - 10
DP  - 2022 Jul
TI  - Mavacamten: First Approval.
PG  - 1127-1135
LID - 10.1007/s40265-022-01739-7 [doi]
AB  - Mavacamten (Camzyos) is an oral small-molecule cardiac myosin inhibitor 
      developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, 
      for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic 
      dysfunction. In April 2022, mavacamten was approved for use in the USA in the 
      treatment of adults with symptomatic New York Heart Association (NYHA) class 
      II-III obstructive HCM to improve functional capacity and symptoms. This article 
      summarizes the milestones in the development of mavacamten leading to this first 
      approval for the treatment of adults with symptomatic NYHA class II-III 
      obstructive HCM.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Keam, Susan J
AU  - Keam SJ
AD  - Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
      dru@adis.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220708
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Benzylamines)
RN  - 0 (MYK-461)
RN  - 56HH86ZVCT (Uracil)
RN  - EC 3.6.1.- (Cardiac Myosins)
SB  - IM
EIN - Drugs. 2022 Jul;82(11):1235. PMID: 35921035
MH  - Adult
MH  - *Benzylamines/pharmacology
MH  - Cardiac Myosins
MH  - *Cardiomyopathy, Hypertrophic/drug therapy
MH  - Humans
MH  - Uracil/analogs & derivatives/pharmacology
PMC - PMC9338109
COIS- During the peer review process the manufacturer of the agent under review was 
      offered an opportunity to comment on the article. Changes resulting from any 
      comments received were made by the authors on the basis of scientific 
      completeness and accuracy. Susan J. Keam is a contracted employee of Adis 
      International Ltd/Springer Nature, and declares no relevant conflicts of 
      interest. All authors contributed to the review and are responsible for the 
      article content.
EDAT- 2022/07/09 06:00
MHDA- 2022/07/30 06:00
PMCR- 2022/07/08
CRDT- 2022/07/08 11:17
PHST- 2022/06/15 00:00 [accepted]
PHST- 2022/07/09 06:00 [pubmed]
PHST- 2022/07/30 06:00 [medline]
PHST- 2022/07/08 11:17 [entrez]
PHST- 2022/07/08 00:00 [pmc-release]
AID - 10.1007/s40265-022-01739-7 [pii]
AID - 1739 [pii]
AID - 10.1007/s40265-022-01739-7 [doi]
PST - ppublish
SO  - Drugs. 2022 Jul;82(10):1127-1135. doi: 10.1007/s40265-022-01739-7. Epub 2022 Jul 
      8.